Swiss pharma giant Novartis has announced that it has agreed to buy UK-based Ziarco Group, a privately-held company focused on the development of new treatments in dermatology. 16 December 2016
Troubled Valeant Pharmaceuticals has announced the departure of three executives, as the business continues to restructure at the close of a punishing 2016. 14 December 2016
Privately-held US firms Purdue Pharma and Exicure have announced a new research collaboration and license agreement aimed at discovering and developing a treatment for psoriasis in a deal that could eventually be worth up to $790 million plus royalties on successful products. 13 December 2016
A strategic global collaboration focusing on the development and commercialization of a novel RORyt inverse agonist (inhibitor) program for treatment of inflammatory skin diseases and disorders as well as for treatment of psoriatic arthritis has been announced. 12 December 2016
The European Medicines Agency has accepted for review the Marketing Authorization Application (MAA) for Dupixent (dupilumab) for the treatment of adults with moderate-to-severe atopic dermatitis (AD) who are candidates for systemic therapy. 8 December 2016
Sienna Biopharmaceuticals has acquired Creabilis, a company focused on developing first-in-class topical treatments for common inflammatory skin conditions. 7 December 2016
Following swiftly on a US regulatory filing, US healthcare giant Johnson & Johnson (NYSE: JNJ) has now applying to get clearance for its blockbuster-potential plaque psoriasis drug. 25 November 2016
Valeant has issued a statement after learning that a criminal complaint was filed in relation to Philidor, a specialty pharmacy which is accused of pushing the products of the Canadian drugmaker. 18 November 2016
Janssen Biotech has filed a Biologics License Application (BLA) with the US Food and Drug Administration approval of its investigational anti-interleukin-23 monoclonal antibody. 17 November 2016
Spain’s leading drugmaker Almirall has reported revenues for 2016’s first three quarters which are 6.7% higher than in the same period last year. 7 November 2016
The US Food and Drug Administration has approved the supplemental Biologics License Application (sBLA) from US biotech giant Amgen for the expanded use of Enbrel (etanercept), making it the first and only systemic therapy to treat pediatric patients (ages four-17) with chronic moderate-to-severe plaque psoriasis. 5 November 2016
US drugmaker Abbott (NYSE: ABT) has officially commissioned a new line for the production of gelatine capsules at its Veropharm plant in the Russian city of Belgorod. 4 November 2016
The National Institute for Health and Care excellence (NICE) has today published draft guidance for US pharma major Eli Lilly’s (ixekizumab) for psoriasis. 1 November 2016
Melinta Therapeutics has submitted New Drug Applications (NDAs) to the US Food and Drug Administration for approval of IV and oral Baxdela (delafloxacin) for the treatment of patients with acute bacterial skin and skin structure infections (ABSSSI). 24 October 2016
Celgene announced today that adult patients in England and Wales with chronic plaque psoriasis will now have access to oral Otezla (apremilast) following a positive final appraisal determination from the National Institute for Health and Care Excellence (NICE). 20 October 2016
Allergan has received the Marketing Authorization for Belkyra (deoxycholic acid) after being granted approval by the Swedish Medical Products Agency (MPA). 13 October 2016
New results from Phase III trials of Dupixent in inadequately controlled moderate-to-severe atopic dermatitis (AD) have been announced by French pharma major Sanofi and US biotech firm Regeneron Pharmaceuticals. 3 October 2016
New findings from the largest global survey ever carried out involving people with psoriasis show that many do not achieve the treatment goal of clear skin or even believe it is a realistic aim. 3 October 2016
Leading Indian drugmaker Sun Pharma and Spain's largest drugmaker, Almirall, have announced positive results in two Phase III trials of tildrakizumab, as a potential treatment for chronic moderate-to-severe plaque psoriasis. 3 October 2016
Greater efficacy in moderate to severe plaque psoriasis than AbbVie’s big-selling Humira (adalimumab) was just one of the findings in data presented on guselkumab, an anti-interleukin-23 monoclonal antibody, by Janssen on Saturday. 1 October 2016
The atopic dermatitis (AD) market is on track to reach $16.7 billion across mature markets by 2030, according to data and analytics company GlobalData. 19 September 2024
Danish clinical-stage techbio firm Evaxion Biotech, which is developing AI-Immunology powered vaccines, announced new clinical Phase II data for its lead compound EVX-01. 9 September 2024
Danish dermatology specialist LEO Pharma has presented a range of new population-level and physician-reported data on the prevalence, severity and treatment of moderate to severe chronic hand eczema (CHE). 5 September 2024
Biocon Biologics has signed a settlement and license agreement with Johnson & Johnson that clears the way to commercialize its Bmab 1200, a proposed biosimilar to Stelara (ustekinumab), in Europe, the UK, Canada, and Japan. 3 September 2024
South Korea’s Celltrion yesterday announced the European Commission (EC) approval for the use of SteQeyma (CT-P43), an ustekinumab biosimilar referencing Stelara, for the treatment of multiple chronic inflammatory diseases. 27 August 2024
Danish dermatology specialist LEO Pharma’s Timber Pharmaceuticals subsidiary has announced disappointing results for the randomized, double-blind 12-week period of the ASCEND trial. 23 August 2024
San Diego, USA-based biotech AnaptysBio (Nasdaq: ANAB) yesterday announced the pricing of an underwritten offering of 2,750,498 shares of its common stock at a price of $36.50 per share, representing a premium of approximately 10% to Anaptys’ closing price on August 13, 2024. 15 August 2024
Shares of American dermatology company Verrica Pharmaceuticals had a roller-coaster start to the day after announcing what it called positive trial results. 14 August 2024
The US Food and Drug Administration (FDA) has approved Galderma’s Nemluvio (nemolizumab) as a pre-filled pen for subcutaneous injection for the treatment of adults with prurigo nodularis. 14 August 2024
The US subsidiary of South Korea’s Celltrion announced its US Food and Drug Administration (FDA)-approved biosimilar adalimumab-aaty has been added to the Costco member prescription program. 14 August 2024
Crown Laboratories, a privately held skincare company, and Nashville, USA-based Revance Therapeutics have entered into an agreement whereby the companies seek to merge the two complementary organizations. 13 August 2024
BioNTech released positive top-line data from the ongoing Phase II clinical trial in patients with unresectable stage III or IV melanoma whose disease had progressed following anti-PD-(L)1-containing treatment. 30 July 2024
California’s Arcutis Biotherapeutics, a biopharma developing innovations in immuno-dermatology, has announced the US commercial launch of Zoryve (roflumilast) cream 0.15% for the treatment of mild to moderate atopic dermatitis in adults and children down to age six years. 30 July 2024
The European Medicines Agency’s (EMA) human medicines committee (CHMP) recommended seven novel medicines for approval at its July 2024 meeting. 26 July 2024
“Circle of Goodness,” one of Russia’s largest public funds, specializing on procurements of drugs for children with rare diseases, will begin procurements of the US drug Vyjuvek (beremagen heperpavec), which is designed for patients with epidermolysis bullosa (butterfly syndrome), reports The Pharma Letter’s local correspondent. 25 July 2024